Status:
COMPLETED
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Lead Sponsor:
Pfizer
Conditions:
Gastrointestinal Stromal Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.
Eligibility Criteria
Inclusion
- Key
- Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent
- Failed Gleevec treatment or intolerant to Gleevec therapy
- Key
Exclusion
- Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational agent since the last dose of Gleevec
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT00075218
Start Date
December 1 2003
End Date
May 1 2008
Last Update
September 28 2009
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Duarte, California, United States, 91010
2
Pfizer Investigational Site
Los Angeles, California, United States, 90095-6984
3
Pfizer Investigational Site
Los Angeles, California, United States, 90095
4
Pfizer Investigational Site
Pasadena, California, United States, 91105